Octreotide effect on growth hormone and somatostatin subtype 2 receptor mRNAs of the human pituitary somatotroph adenomas

Endocrine Pathology

Volumn 11, Issue 1, 2000, Pages 41-48

  Stefaneanu, Lucia ^a   Kovacs, Kalman ^a   Thapar, Kamal ^a   Horvath, Eva ^a   Melmed, Shlomo ^b   Greenman, Yona ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GH mRNA; In situ hybridization; Octreotide; Pituitary somatotroph adenomas; SSTR 2 mRNA

Indexed keywords

GROWTH HORMONE RECEPTOR; MESSENGER RNA; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR;

ARTICLE; CELL GRANULE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IN SITU HYBRIDIZATION; PRIORITY JOURNAL;

EID: 0034075475     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:11:1:41     Document Type: Article

References (41)

1. 1. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology 136:4174-4181, 1995.
2. 2. Todisco A, Campbell V, Dickinson CJ, et al. Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding. Am J Physiol 267:G245-G253, 1994.
3. 3. Srikant CB. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun 209:400-406, 1995.
4. 4. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 16:427-442, 1995.
5. 5. O'Carroll AM, Lolait SJ, Konig M, et al. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol 42:939-946, 1992.
6. 6. O'Carroll AM, Raynor K, Lolait SJ, et al. Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol 46:291-298, 1994.
7. 7. Kumar U, Laird D, Srikant CB, et al. Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138:4473-4476, 1997.
8. 8. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386-1392, 1995.
9. 9. Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576-1580, 1985.
10. 10. Ducasse MC, Tauber JP, Tourre A, et al. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 65:1042-1046, 1987.
11. 11. Plockinger U, Reichel M, Fett U, et al. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79:1416-1423, 1994.
12. 12. Lamberts SW. Acromegaly and its treatment. J Endocrinol 155 Suppl 1:S49-S51, 1997.
13. 13. Thapar K, Kovacs KT, Stefaneanu L, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 72:893-900, 1997.
14. 14. Sautner D, Saeger W, Tallen G, et al. Effects of octreotide on morphology of pituitary adenomas in acromegaly. Pathol Res Pract 189:1044-1051, 1993.
15. 15. Ezzat S, Horvath E, Harris AG, et al. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79:113-118, 1994.
16. 16. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398-403, 1994.
17. 17. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729, 1994.
18. 18. Murabe H, Shimatsu A, Ihara C, et al. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. J Neuroendocrinol 8:605-610, 1996.
19. 19. Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392, 1997.
20. 20. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282:737-740, 1998.
21. 21. Stefaneanu L, Kovacs K, Lloyd RV, et al. Pituitary lactotrophs and somatotrophs in pregnancy: a correlative in situ hybridization and immunocytochemical study. Virchows Arch B Cell Pathol 62:291-296, 1992.
22. 22. Bertherat J, Chanson P, Dewailly D, et al. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metab 77:1577-1583, 1993.
23. 23. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 9:417-436, 1988.
24. 24. Presky DH, Schonbrunn A. Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 263:714-721, 1988.
25. 25. Li J, Stefaneanu L, Kovacs K, et al. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH-and PRL-producing human pituitary adenomas. Virchows Arch A Pathol Anat Histopathol 422:193-201, 1993.
26. 26. Yamada S, Takahashi M, Hara M, et al. Growth hormone and prolactin gene expression in human densely and sparsely granulated somatotroph adenomas by in situ hybridization with digoxigenin-labeled probes. Diagn Mol Pathol 3:46-52, 1994.
27. 27. Hofland LJ, Velkeniers B, Lely AJ, et al. Long-term in vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels. Clin Endocrinol (Oxf) 37:240-248, 1992.
28. 28. Barinaga M, Bilezikjian LM, Vale WW, et al. Independent effects of growth hormone releasing factor on growth hormone release and gene transcription. Nature 314:279-281, 1985.
29. 29. Namba H, Morita S, Melmed S. Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic acid levels: interaction with somatostatin. Endocrinology 124:1794-1799, 1989.
30. 30. Levy A, Lightman SL. Quantitative in-situ hybridization histochemistry studies on growth hormone (GH) gene expression in acromegalic somatotrophs: effects of somatostatin, GH-releasing factor and cortisol. J Mol Endocrinol 1:19-26, 1988.
31. 31. Davis JR, Wilson EM, Vidal ME, et al. Regulation of growth hormone secretion and messenger ribonucleic acid accumulation in human somatotropinoma cells in vitro. J Clin Endocrinol Metab 69:704-708, 1989.
32. 32. Silverman BL, Bettendorf M, Kaplan SL, et al. Regulation of growth hormone (GH) secretion by GH-releasing factor, somatostatin, and insulin-like growth factor I in ovine fetal and neonatal pituitary cells in vitro. Endocrinology 124:84-89, 1989.
33. 33. Wood DF, Docherty K, Ramsden DB, et al. A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro. Mol Cell Endocrinol 52:257-261, 1987.
34. 34. Sugihara H, Minami S, Okada K, et al. Somatostatin reduces transcription of the growth hormone gene in rats. Endocrinology 132:1225-1229, 1993.
35. 35. Yamada S, Aiba T, Sano T, et al. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20-27, 1993.
36. 36. Pagesy P, Li JY, Rentier-Delrue F, et al. Evidence of pre-prosomatostatin mRNA in human normal and tumoral anterior pituitary gland. Mol Endocrinol 3:1289-1294, 1989.
37. 37. Joubert D, Benlot C, Lagoguey A, et al. Normal and growth hormone (GH)-secreting adenomatous human pituitaries release somatostatin and GH-releasing hormone. J Clin Endocrinol Metab 68:572-577, 1989.
38. 38. Alberti VN. Immunohistochemical demonstration of insulin-like growth factor I (IGF-1) in normal and pathological human pituitary glands. Pathol Res Pract 187:541-542, 1991.
39. 39. Thapar K, Kovacs K, Stefaneanu L, et al. Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am J Pathol 151:769-784, 1997.
40. 40. Pagesy P, Li JY, Rentier-Delrue F, et al. Growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation. Acta Endocrinol(Copenh) 122:745-752, 1990.
41. 41. Benlot C, Pagesy P, Peillon F, et al. Growth hormone-releasing hormone and somatostatin in normal and tumoral human pituitaries. Peptides 12:945-950, 1991.